Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases

Contributed by: PR Newswire

Tags

Genomics-Greywolf

More Like This

Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

PR Newswire associated0

Werfen Receives CE Mark for Aptiva® Antiphospholipid Syndrome Reagents

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting

Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients

BioMed X Launches a New Call for Application in Autoimmune Disease Research

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results